ORTHO DEVELOPMENT BALANCED KNEE SYSTEM

K994370 · Ortho Development Corp. · JWH · Mar 24, 2000 · Orthopedic

Device Facts

Record IDK994370
Device NameORTHO DEVELOPMENT BALANCED KNEE SYSTEM
ApplicantOrtho Development Corp.
Product CodeJWH · Orthopedic
Decision DateMar 24, 2000
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Ortho Development Balanced Knee™ System is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as rheumatoid arthritis or osteoarthritis. primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, pseudo-gout, or complications from a previous prosthesis. This device is intended for cemented use only.

Device Story

Balanced Knee™ System is a semi-constrained total knee replacement prosthesis; comprises femoral, tibial, and patellar components. Designed for surgical implantation to replace diseased or arthritic knee joints; restores joint function. Used in clinical settings by orthopedic surgeons. Device functions as a mechanical replacement for damaged bone and cartilage; cemented fixation required. Benefits patients by alleviating pain and restoring mobility in cases of severe degenerative bone disease, arthritis, or post-traumatic joint damage.

Clinical Evidence

No clinical data provided; substantial equivalence based on design, material, and functional comparison to legally marketed predicate devices.

Technological Characteristics

Semi-constrained knee prosthesis. Materials: CoCr alloy (cast or wrought), Ti-6Al-4V alloy, and UHMWPE per ASTM standards. Cemented fixation. Mechanical device; no software or energy source.

Indications for Use

Indicated for patients with severe knee pain and disability requiring primary total knee replacement. Includes conditions: osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, loss of joint configuration/function, and moderate valgus, varus, or flexion deformities. Intended for single use; cemented only.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ MAR 2 4 2 100 # SUMMARY OF SAFETY AND EFFECTIVENESS: This safety and effectiveness summary for the Ortho Development Balanced Knee™ System is provided as required per Section 513(i)(3) of the Food, Drug, and Cosmetic Act. - 1. Submitter: Ortho Development Corporation 106 West 12200 South Draper, Utah 84020 - 2. Contact Person: Carol Freasier Telephone: (801) 553-9991 Fax: (801) 553-9993 - Ortho Development Balanced Knee™ System 3. Trade Name: Balanced Knee™ System Common Name: Classification Name: Prosthesis, Knee patellofemorotibial, Semi-constrained, Cemented, Polymer/Metal/Polymer (888.3560) ## 4. Predicate or legally marketed devices which are substantially equivalent: - Performance Total Knee System (Kirschner) ● - NexGen Total Knee System (Zimmer) . - PCA Modular Total Knee System (Howmedica) ● - Natural Knee System (Intermedics) . - AGC Modular Total Knee System (Biomet) . - Foundation Total Knee System (Encore) . ## 5. Description of the device: The Ortho Development Balanced Knee™ System is a semi-constrained total knee replacement system, consisting of femoral, tibial and patellar components. - The devices are manufactured from CoCr alloy (cast or Wrought), Ti-6Al-4V alloy Materials: and Ultra High Molecular Weight Polyethylene (UHMWPE) per ASTM standards, - The system functions to provide restoration of function as a replacement for Function: diseased and arthritic knees. ### 6. Intended Use: The Ortho Development Balanced Knee™ System is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as rheumatoid arthritis or osteoarthritis. primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, pseudo-gout, or complications from a previous prosthesis. This device is intended for cemented use only. - 7. Comparison of the technological characteristics of the device to predicate and legally marketed devices: There are no significant differences between the Ortho Development Balanced Knee™ System and the systems currently being marketed which would adversely affect the use of the product. It is substantially equivalent to these other devices in design, function, material and intended use. {1}------------------------------------------------ Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The eagle is facing left and has three lines representing its wings. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 MAR 2 4 2000 Ms. Carol Freasier Regulatory Affairs / Quality Assurance Ortho Development Corporation 106 West 12200 South Draper. Utah 84020 Re: K994370 Trade Name: Ortho Development Balanced KneerM System Regulatory Class: II Product Code: JWH Dated: December 23, 1999 Received: December 27, 1999 Dear Ms. Freasier: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. {2}------------------------------------------------ Page 2 - Ms. Carol Freasier If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device. please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Styph Ruoch Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ Device Name: Balanced Knee™ System #### Indications for Use The Balanced Knee™ System is intended for single use in primary total knee replacement only. Indications include: - Loss of joint configuration and joint function: ● - Osteoarthritis of the knee joint; - Rheumatoid arthritis of the knee joint; . - Post-traumatic arthritis of the knee joint; . - . Moderate valgus, varus, or flexion deformities. ### (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) ## Concurrence of CDRH, Office of Device Evaluation (ODE) Division Sign-Off) · livision of General Restorative 994370 510(k) Number . Prescription Use (Per 21 CFR 801.109) OR Over-The Courter Use (Optional Format 1-2-96)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%